Research ExplorerPublicationsSex differences in adverse events from systemic treatments f...

Sex differences in adverse events from systemic treatments for psoriasis: A decade of insights from the Swiss Psoriasis Registry (SDNTT)

Standard

Sex differences in adverse events from systemic treatments for psoriasis: A decade of insights from the Swiss Psoriasis Registry (SDNTT). / Verardi, Fabio; Maul, Lara Valeska; Borsky, Kim; Steinmann, Simona; Rosset, Nina; Pons, Hector Ortega; Sorbe, Christina; Yawalkar, Nikhil; Micheroli, Raphael; Egeberg, Alexander; Thyssen, Jacob P; Heidemeyer, Kristine; Boehncke, Wolf-Henning; Conrad, Curdin; Cozzio, Antonio; Pinter, Andreas; Kündig, Thomas; Navarini, Alexander A; Maul, Julia-Tatjana.

In: J EUR ACAD DERMATOL, Vol. 38, No. 4, 04.2024, p. 719-731.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Verardi, F, Maul, LV, Borsky, K, Steinmann, S, Rosset, N, Pons, HO, Sorbe, C, Yawalkar, N, Micheroli, R, Egeberg, A, Thyssen, JP, Heidemeyer, K, Boehncke, W-H, Conrad, C, Cozzio, A, Pinter, A, Kündig, T, Navarini, AA & Maul, J-T 2024, 'Sex differences in adverse events from systemic treatments for psoriasis: A decade of insights from the Swiss Psoriasis Registry (SDNTT)', J EUR ACAD DERMATOL, vol. 38, no. 4, pp. 719-731. https://doi.org/10.1111/jdv.19730

APA

Verardi, F., Maul, L. V., Borsky, K., Steinmann, S., Rosset, N., Pons, H. O., Sorbe, C., Yawalkar, N., Micheroli, R., Egeberg, A., Thyssen, J. P., Heidemeyer, K., Boehncke, W-H., Conrad, C., Cozzio, A., Pinter, A., Kündig, T., Navarini, A. A., & Maul, J-T. (2024). Sex differences in adverse events from systemic treatments for psoriasis: A decade of insights from the Swiss Psoriasis Registry (SDNTT). J EUR ACAD DERMATOL, 38(4), 719-731. https://doi.org/10.1111/jdv.19730

Vancouver

Verardi F, Maul LV, Borsky K, Steinmann S, Rosset N, Pons HO et al. Sex differences in adverse events from systemic treatments for psoriasis: A decade of insights from the Swiss Psoriasis Registry (SDNTT). J EUR ACAD DERMATOL. 2024 Apr;38(4):719-731. https://doi.org/10.1111/jdv.19730

Bibtex

@article{300aeca25add4b64a720318143261c18,
title = "Sex differences in adverse events from systemic treatments for psoriasis: A decade of insights from the Swiss Psoriasis Registry (SDNTT)",
abstract = "BACKGROUND: Psoriasis is a disease that often requires prolonged systemic treatment. It is important to determine the safety of available therapies. There is currently little insight into sex-specific differences in the safety of systemic psoriasis therapies.OBJECTIVES: To examine the real-world, long-term safety of systemic psoriasis therapies with sex stratification in drug-related adverse events (ADRs).METHODS: Ten-year data from adults with moderate-to-severe psoriasis requiring systemic treatment (conventional systemic therapies [CST], biologics) were obtained from the Swiss psoriasis registry (SDNTT). ADRs were categorized according to the international terminology Medical Dictionary for Regulatory Activities (MedDRA). Safety was assessed by calculating event rates per 100 patient-years (PY). We used descriptive statistics for patient and disease characteristics, and binomial and t-tests to compare treatment groups and sex.RESULTS: In total, 791 patients (290 females) were included with a mean age of 46 years. 358 (45%) received CSTs and 433 (55%) biologics; both groups had similar baseline characteristics except for more joint involvement in patients using biologics (26.86% vs. 14.8%, p < 0.0001). CSTs were associated with a 2.2-fold higher ADR rate (40.43/100 PY vs. 18.22/100 PY, p < 0.0001) and an 8.0-fold higher drug-related discontinuation rate than biologics (0.16/PY vs. 0.02/PY, p < 0.0001). Trends showed non-significant higher serious adverse event rates per 100 PY for biologics (8.19, CI 6.87-9.68) compared to CSTs (7.08, CI 5.39-9.13) (p = 0.3922). Sex stratification revealed a significantly higher overall ADR rate for all treatments in females (1.8-fold for CSTs [57.30/100 PY vs. 31.69/100 PY] and 2.0-fold for biologics [27.36/100 PY vs. 13.9/100 PY], p < 0.0001), and drug-related discontinuation rates for most CSTs in females.CONCLUSION: Females were associated with a significantly higher rate of ADRs and drug-related discontinuation rates. Sex stratification should be taken into consideration when designing studies in the patient-tailored management of psoriasis.",
author = "Fabio Verardi and Maul, {Lara Valeska} and Kim Borsky and Simona Steinmann and Nina Rosset and Pons, {Hector Ortega} and Christina Sorbe and Nikhil Yawalkar and Raphael Micheroli and Alexander Egeberg and Thyssen, {Jacob P} and Kristine Heidemeyer and Wolf-Henning Boehncke and Curdin Conrad and Antonio Cozzio and Andreas Pinter and Thomas K{\"u}ndig and Navarini, {Alexander A} and Julia-Tatjana Maul",
note = "{\textcopyright} 2023 European Academy of Dermatology and Venereology.",
year = "2024",
month = apr,
doi = "10.1111/jdv.19730",
language = "English",
volume = "38",
pages = "719--731",
journal = "J EUR ACAD DERMATOL",
issn = "0926-9959",
publisher = "Wiley-Blackwell",
number = "4",

}

RIS

TY - JOUR

T1 - Sex differences in adverse events from systemic treatments for psoriasis: A decade of insights from the Swiss Psoriasis Registry (SDNTT)

AU - Verardi, Fabio

AU - Maul, Lara Valeska

AU - Borsky, Kim

AU - Steinmann, Simona

AU - Rosset, Nina

AU - Pons, Hector Ortega

AU - Sorbe, Christina

AU - Yawalkar, Nikhil

AU - Micheroli, Raphael

AU - Egeberg, Alexander

AU - Thyssen, Jacob P

AU - Heidemeyer, Kristine

AU - Boehncke, Wolf-Henning

AU - Conrad, Curdin

AU - Cozzio, Antonio

AU - Pinter, Andreas

AU - Kündig, Thomas

AU - Navarini, Alexander A

AU - Maul, Julia-Tatjana

N1 - © 2023 European Academy of Dermatology and Venereology.

PY - 2024/4

Y1 - 2024/4

N2 - BACKGROUND: Psoriasis is a disease that often requires prolonged systemic treatment. It is important to determine the safety of available therapies. There is currently little insight into sex-specific differences in the safety of systemic psoriasis therapies.OBJECTIVES: To examine the real-world, long-term safety of systemic psoriasis therapies with sex stratification in drug-related adverse events (ADRs).METHODS: Ten-year data from adults with moderate-to-severe psoriasis requiring systemic treatment (conventional systemic therapies [CST], biologics) were obtained from the Swiss psoriasis registry (SDNTT). ADRs were categorized according to the international terminology Medical Dictionary for Regulatory Activities (MedDRA). Safety was assessed by calculating event rates per 100 patient-years (PY). We used descriptive statistics for patient and disease characteristics, and binomial and t-tests to compare treatment groups and sex.RESULTS: In total, 791 patients (290 females) were included with a mean age of 46 years. 358 (45%) received CSTs and 433 (55%) biologics; both groups had similar baseline characteristics except for more joint involvement in patients using biologics (26.86% vs. 14.8%, p < 0.0001). CSTs were associated with a 2.2-fold higher ADR rate (40.43/100 PY vs. 18.22/100 PY, p < 0.0001) and an 8.0-fold higher drug-related discontinuation rate than biologics (0.16/PY vs. 0.02/PY, p < 0.0001). Trends showed non-significant higher serious adverse event rates per 100 PY for biologics (8.19, CI 6.87-9.68) compared to CSTs (7.08, CI 5.39-9.13) (p = 0.3922). Sex stratification revealed a significantly higher overall ADR rate for all treatments in females (1.8-fold for CSTs [57.30/100 PY vs. 31.69/100 PY] and 2.0-fold for biologics [27.36/100 PY vs. 13.9/100 PY], p < 0.0001), and drug-related discontinuation rates for most CSTs in females.CONCLUSION: Females were associated with a significantly higher rate of ADRs and drug-related discontinuation rates. Sex stratification should be taken into consideration when designing studies in the patient-tailored management of psoriasis.

AB - BACKGROUND: Psoriasis is a disease that often requires prolonged systemic treatment. It is important to determine the safety of available therapies. There is currently little insight into sex-specific differences in the safety of systemic psoriasis therapies.OBJECTIVES: To examine the real-world, long-term safety of systemic psoriasis therapies with sex stratification in drug-related adverse events (ADRs).METHODS: Ten-year data from adults with moderate-to-severe psoriasis requiring systemic treatment (conventional systemic therapies [CST], biologics) were obtained from the Swiss psoriasis registry (SDNTT). ADRs were categorized according to the international terminology Medical Dictionary for Regulatory Activities (MedDRA). Safety was assessed by calculating event rates per 100 patient-years (PY). We used descriptive statistics for patient and disease characteristics, and binomial and t-tests to compare treatment groups and sex.RESULTS: In total, 791 patients (290 females) were included with a mean age of 46 years. 358 (45%) received CSTs and 433 (55%) biologics; both groups had similar baseline characteristics except for more joint involvement in patients using biologics (26.86% vs. 14.8%, p < 0.0001). CSTs were associated with a 2.2-fold higher ADR rate (40.43/100 PY vs. 18.22/100 PY, p < 0.0001) and an 8.0-fold higher drug-related discontinuation rate than biologics (0.16/PY vs. 0.02/PY, p < 0.0001). Trends showed non-significant higher serious adverse event rates per 100 PY for biologics (8.19, CI 6.87-9.68) compared to CSTs (7.08, CI 5.39-9.13) (p = 0.3922). Sex stratification revealed a significantly higher overall ADR rate for all treatments in females (1.8-fold for CSTs [57.30/100 PY vs. 31.69/100 PY] and 2.0-fold for biologics [27.36/100 PY vs. 13.9/100 PY], p < 0.0001), and drug-related discontinuation rates for most CSTs in females.CONCLUSION: Females were associated with a significantly higher rate of ADRs and drug-related discontinuation rates. Sex stratification should be taken into consideration when designing studies in the patient-tailored management of psoriasis.

U2 - 10.1111/jdv.19730

DO - 10.1111/jdv.19730

M3 - SCORING: Journal article

C2 - 38084852

VL - 38

SP - 719

EP - 731

JO - J EUR ACAD DERMATOL

JF - J EUR ACAD DERMATOL

SN - 0926-9959

IS - 4

ER -